HC Wainwright Lowers Earnings Estimates for Legend Biotech

Legend Biotech Co. (NASDAQ:LEGN - Free Report) - Stock analysts at HC Wainwright decreased their Q2 2025 earnings per share (EPS) estimates for shares of Legend Biotech in a note issued to investors on Wednesday, November 13th. HC Wainwright analyst M. Kapoor now forecasts that the company will earn $0.24 per share for the quarter, down from their previous forecast of $0.28. HC Wainwright currently has a "Buy" rating and a $73.00 target price on the stock. The consensus estimate for Legend Biotech's current full-year earnings is ($1.48) per share. HC Wainwright also issued estimates for Legend Biotech's Q4 2025 earnings at $0.12 EPS.

Legend Biotech (NASDAQ:LEGN - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.56) by $0.22. The firm had revenue of $160.20 million for the quarter, compared to the consensus estimate of $143.91 million. Legend Biotech had a negative return on equity of 29.22% and a negative net margin of 66.92%. The company's quarterly revenue was up 66.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.17) EPS.

A number of other research firms have also issued reports on LEGN. Redburn Atlantic initiated coverage on Legend Biotech in a research note on Tuesday, October 8th. They set a "buy" rating and a $86.00 target price for the company. Scotiabank boosted their price objective on Legend Biotech from $70.00 to $76.00 and gave the stock a "sector outperform" rating in a research report on Monday, August 12th. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and issued a $86.00 target price on shares of Legend Biotech in a report on Tuesday, October 29th. Thirteen research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $81.46.

Legend Biotech Stock Up 1.4 %

Shares of NASDAQ:LEGN traded up $0.54 during trading on Thursday, hitting $39.89. The company's stock had a trading volume of 1,630,092 shares, compared to its average volume of 1,094,785. Legend Biotech has a fifty-two week low of $38.60 and a fifty-two week high of $70.13. The business has a 50 day moving average price of $46.49 and a two-hundred day moving average price of $48.34. The company has a debt-to-equity ratio of 0.25, a quick ratio of 4.78 and a current ratio of 4.84. The company has a market capitalization of $7.27 billion, a PE ratio of -41.42 and a beta of 0.11.

Hedge Funds Weigh In On Legend Biotech

Large investors have recently bought and sold shares of the stock. Blue Trust Inc. boosted its position in shares of Legend Biotech by 10,075.0% in the 2nd quarter. Blue Trust Inc. now owns 814 shares of the company's stock valued at $36,000 after purchasing an additional 806 shares during the period. American International Group Inc. boosted its holdings in shares of Legend Biotech by 50.0% in the first quarter. American International Group Inc. now owns 900 shares of the company's stock valued at $50,000 after acquiring an additional 300 shares during the period. AM Squared Ltd purchased a new position in shares of Legend Biotech during the second quarter worth approximately $71,000. Quantbot Technologies LP acquired a new position in shares of Legend Biotech in the 3rd quarter valued at $148,000. Finally, California State Teachers Retirement System raised its position in Legend Biotech by 196.3% in the 1st quarter. California State Teachers Retirement System now owns 3,345 shares of the company's stock valued at $188,000 after purchasing an additional 2,216 shares during the last quarter. Institutional investors and hedge funds own 70.89% of the company's stock.

About Legend Biotech

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).